Ozempic is approved for type 2 diabetes and has no weight-loss indication. CT-388 is not approved for anything and has one published trial lasting 29 days. The two have never been studied in the same population for the same purpose, and no comparison between them is currently possible.
What each one is
| CT-388 | Ozempic | |
|---|---|---|
| Status | Investigational, phase 3 | FDA approved |
| Approved for | — | Type 2 diabetes |
| Targets | GLP-1 and GIP, signalling-biased | GLP-1 |
| Weight data | up to 8.0% at day 29 (phase 1) | No weight endpoint in label |
| Diabetes data | Glycaemic measures improved in phase 1 | HbA1c ~−1.5 to −1.8% |
| Cardiovascular indication | No | Yes, in type 2 diabetes |
| Can you get it | No | Yes |
Why this comparison does not work
Ozempic has no weight figure. It is licensed for type 2 diabetes and its label publishes no weight endpoint. The 14.9% usually attributed to it belongs to Wegovy — the same molecule at 2.4 mg against Ozempic's 2 mg ceiling.
CT-388 has no meaningful diabetes figure. Its phase 1 reported improved glycaemic measures during fasting and an oral glucose tolerance test, in healthy volunteers over four weeks. That is a pharmacological observation, not a demonstration of diabetes treatment.
So each has data in the area the other does not, and neither has enough to place beside the other.
The question worth asking instead
If you are on Ozempic and reading about CT-388, the useful comparison is against the drug class that already beat single-receptor GLP-1 agonists: tirzepatide. CT-388 targets the same two receptors tirzepatide does, so CT-388 vs Zepbound is the comparison it is actually built for.
If your interest is weight loss specifically, the semaglutide product with a weight indication is Wegovy, not Ozempic — see CT-388 vs Wegovy.
What Ozempic has today
- An approval with a licensed indication, a known dose and a pharmacy that dispenses it.
- A cardiovascular indication in adults with type 2 diabetes and established cardiovascular disease.
- Insurance coverage, which diabetes drugs receive where weight drugs are refused.
- Years of post-marketing data — the only way rare effects surface.
CT-388 has a phase 1 trial and a phase 3 programme that is recruiting. It cannot be prescribed.
Scientific References
2 sources- 1
Chakravarthy MV, Rodriguez R, Hergarden A, et al.
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
Molecular Metabolism · 103 · 2026PMID: 41319798
NIH - 2
Novo Nordisk
Ozempic (semaglutide) — indication, dosing and self-pay pricing, NovoCare Pharmacy; verified August 2026
Manufacturer prescribing and pricing information · 2026
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is CT-388 better than Ozempic?
No evidence supports an answer. Ozempic is licensed for type 2 diabetes and publishes no weight endpoint; CT-388's only published trial ran 29 days in healthy volunteers. Each has data where the other does not. The comparison CT-388 is actually built for is against tirzepatide, since it targets the same two receptors.
Does CT-388 treat diabetes?
Not demonstrated. Its phase 1 trial reported improved glycaemic measures during fasting and an oral glucose tolerance test, in otherwise healthy participants over four weeks. That is a pharmacological signal, not evidence of treating type 2 diabetes, and no diabetes trial has been published.
Which is better for weight loss, CT-388 or Ozempic?
Ozempic has no weight-loss indication and no weight endpoint in its label, so there is no official figure to compare against. The 14.9% often attributed to it belongs to Wegovy, the same molecule at a higher dose. CT-388's only figure is up to 8% at day 29, which cannot be compared with anything measured over a year.
Should I switch from Ozempic to CT-388?
You cannot. CT-388 is not approved anywhere, so no clinician can prescribe it and no pharmacy can dispense it. It is in phase 3 and recruiting, which means a trial is the only legitimate route to receiving it.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.